292 related articles for article (PubMed ID: 30024860)
1. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.
Fontán L; Qiao Q; Hatcher JM; Casalena G; Us I; Teater M; Durant M; Du G; Xia M; Bilchuk N; Chennamadhavuni S; Palladino G; Inghirami G; Philippar U; Wu H; Scott DA; Gray NS; Melnick A
J Clin Invest; 2018 Oct; 128(10):4397-4412. PubMed ID: 30024860
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
Ferch U; Kloo B; Gewies A; Pfänder V; Düwel M; Peschel C; Krappmann D; Ruland J
J Exp Med; 2009 Oct; 206(11):2313-20. PubMed ID: 19841089
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.
Nagel D; Spranger S; Vincendeau M; Grau M; Raffegerst S; Kloo B; Hlahla D; Neuenschwander M; Peter von Kries J; Hadian K; Dörken B; Lenz P; Lenz G; Schendel DJ; Krappmann D
Cancer Cell; 2012 Dec; 22(6):825-37. PubMed ID: 23238017
[TBL] [Abstract][Full Text] [Related]
4. Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-κB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells.
Wu CH; Yang YH; Chen MR; Tsai CH; Cheng AL; Doong SL
PLoS One; 2018; 13(6):e0199779. PubMed ID: 29953499
[TBL] [Abstract][Full Text] [Related]
5. Development of new Malt1 inhibitors and probes.
Xin BT; Schimmack G; Du Y; Florea BI; van der Marel GA; Driessen C; Krappmann D; Overkleeft HS
Bioorg Med Chem; 2016 Aug; 24(15):3312-29. PubMed ID: 27085674
[TBL] [Abstract][Full Text] [Related]
6. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL.
Fontan L; Goldstein R; Casalena G; Durant M; Teater MR; Wilson J; Phillip J; Xia M; Shah S; Us I; Shinglot H; Singh A; Inghirami G; Melnick A
Blood; 2021 Feb; 137(6):788-800. PubMed ID: 32785655
[TBL] [Abstract][Full Text] [Related]
7. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.
Hailfinger S; Lenz G; Ngo V; Posvitz-Fejfar A; Rebeaud F; Guzzardi M; Penas EM; Dierlamm J; Chan WC; Staudt LM; Thome M
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19946-51. PubMed ID: 19897720
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
9. GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein.
Cheng J; Klei LR; Hubel NE; Zhang M; Schairer R; Maurer LM; Klei HB; Kang H; Concel VJ; Delekta PC; Dang EV; Mintz MA; Baens M; Cyster JG; Parameswaran N; Thome M; Lucas PC; McAllister-Lucas LM
J Clin Invest; 2020 Feb; 130(2):1036-1051. PubMed ID: 31961340
[TBL] [Abstract][Full Text] [Related]
10. Antiapoptotic properties of MALT1 protease are associated with redox homeostasis in ABC-DLBCL cells.
Zhu L; Tang F; Lei Z; Guo C; Song Y; Huang J; Xia X
Mol Carcinog; 2019 Dec; 58(12):2340-2352. PubMed ID: 31556968
[TBL] [Abstract][Full Text] [Related]
11. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.
Fontan L; Yang C; Kabaleeswaran V; Volpon L; Osborne MJ; Beltran E; Garcia M; Cerchietti L; Shaknovich R; Yang SN; Fang F; Gascoyne RD; Martinez-Climent JA; Glickman JF; Borden K; Wu H; Melnick A
Cancer Cell; 2012 Dec; 22(6):812-24. PubMed ID: 23238016
[TBL] [Abstract][Full Text] [Related]
12. Peptide-based covalent inhibitors of MALT1 paracaspase.
Hatcher JM; Du G; Fontán L; Us I; Qiao Q; Chennamadhavuni S; Shao J; Wu H; Melnick A; Gray NS; Scott DA
Bioorg Med Chem Lett; 2019 Jun; 29(11):1336-1339. PubMed ID: 30954428
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.
Fontán L; Melnick A
Clin Cancer Res; 2013 Dec; 19(24):6662-8. PubMed ID: 24004675
[TBL] [Abstract][Full Text] [Related]
14. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
Seshadri MR; Melnick AM
Leuk Lymphoma; 2022 Apr; 63(4):789-798. PubMed ID: 34783281
[TBL] [Abstract][Full Text] [Related]
15. Attacking MALT1 for ABC-DLBCL therapy.
Krappmann D
Oncotarget; 2012 Dec; 3(12):1489-90. PubMed ID: 23455231
[No Abstract] [Full Text] [Related]
16. MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas.
Minderman M; Lantermans HC; Grüneberg LJ; Cillessen SAGM; Bende RJ; van Noesel CJM; Kersten MJ; Pals ST; Spaargaren M
Blood Cancer J; 2023 Mar; 13(1):37. PubMed ID: 36922488
[TBL] [Abstract][Full Text] [Related]
17. Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas.
Wimberger N; Ober F; Avar G; Grau M; Xu W; Lenz G; Menden MP; Krappmann D
Blood; 2023 Dec; 142(23):1985-2001. PubMed ID: 37623434
[TBL] [Abstract][Full Text] [Related]
18. Targeting lymphomas through MALT1 inhibition.
Fontan L; Melnick A
Oncotarget; 2012 Dec; 3(12):1493-4. PubMed ID: 23455603
[No Abstract] [Full Text] [Related]
19. The protease activity of the paracaspase MALT1 is controlled by monoubiquitination.
Pelzer C; Cabalzar K; Wolf A; Gonzalez M; Lenz G; Thome M
Nat Immunol; 2013 Apr; 14(4):337-45. PubMed ID: 23416615
[TBL] [Abstract][Full Text] [Related]
20. Identification of Tensin-3 as a MALT1 substrate that controls B cell adhesion and lymphoma dissemination.
Juilland M; Alouche N; Ubezzi I; Gonzalez M; Rashid HO; Scarpellino L; Erdmann T; Grau M; Lenz G; Luther SA; Thome M
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2301155120. PubMed ID: 38109544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]